Drug · CHEMBL22

TRIMETHOPRIM

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. TRIMETHOPRIM. Drugs and targets, record CHEMBL22. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL22

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: TRIMETHOPRIM; ChEMBL
ChEMBL ID: CHEMBL22; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Ipral, Ledatrim, Monotrim, Proloprim, Proloprin, Syraprim, Tiempe, Trimethoprim component of bactrim, Trimethoprim component of bactrim ds, Trimethoprim component of bactrim pediatric, Trimethoprim component of co-trimoxazole, Trimethoprim component of cotrim, Trimethoprim component of cotrim d.s., Trimethoprim component of septra, Trimethoprim component of sulfamethoprim, Trimethoprim component of sulfatrim, Trimethoprim component of sulmeprim, Trimethoprim component of uroplus, Trimogal, Trimopan, Trimpex, Trimpex 200, Triprimix 200; ChEMBL
Other names: BW 56-72, BW-56-72, Infectotrimet, NIH-204, NSC-106568, TCMDC-125538, Trimethoprime, Trimethoprimum, Trimetoprima, Wellcoprim; ChEMBL
DrugBank: DB00440; DrugBank
InChIKey: IEDVJHCEMCRBQM-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 5 of its 37 diseases, from ATC, DailyMed, FDA and TTD; Open Targets

Targets0

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

None in this release.

Diseases37

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
pneumocystosis	Approval	DailyMed	75	10	https://conductscience.org/library/drugs?q=MONDO_0019121
Cutaneous abscess	Phase 3	ClinicalTrials.gov	7	7	https://conductscience.org/library/drugs?q=HP_0031292
urinary tract infection	Approval	DailyMed, FDA and TTD	94	6	https://conductscience.org/library/drugs?q=MONDO_0100338
methicillin-resistant staphylococcus aureus infectious disease	Phase 3	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0100073
cellulitis	Phase 2/3	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0005230
Lymphoma, AIDS-Related	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=EFO_1001365
abscess	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0005227
cystic fibrosis	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0009061
idiopathic pulmonary fibrosis	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=EFO_0000768
infection	Approval	DailyMed	114	1	https://conductscience.org/library/drugs?q=EFO_0000544

1 to 10 of 37Source Open Targets

See all 37 diseases

Trials132

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 4 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 15 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00729937	Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"	Phase 2/3	2,265	2014-05-28	trimethoprim-sulfamethoxazole	A combination that names it	ClinicalTrials.gov
NCT01650558	Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi		1,499	2021-05-19	trimethoprim-sulfamethoxazole	A combination that names it	ClinicalTrials.gov
NCT00730028	Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus	Phase 2	1,310	2016-03-17	trimethoprim-sulfamethoxazole	A combination that names it	ClinicalTrials.gov
NCT01595529	The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"	Phase 2	717	2020-07-13	trimethoprim-sulfamethoxazole	A combination that names it	ClinicalTrials.gov
NCT00405704	Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)	Phase 3	607	2015-04-16	trimethoprim-sulfamethoxazole	A combination that names it	ClinicalTrials.gov
NCT00948896	Chemopreventive Therapy for Malaria in Ugandan Children	Phase 3	600	2015-08-04	trimethoprim-sulfamethoxazole	A combination that names it	ClinicalTrials.gov
NCT01659866	Antibiotic Prophylaxis for Transrectal Prostate Biopsy	Phase 4	563	2019-06-25	trimethoprim-sulfamethoxazole	A combination that names it	ClinicalTrials.gov
NCT02759120	CleanUP IPF for the Pulmonary Trials Cooperative	Phase 3	513	2021-03-03	trimethoprim	Its name	ClinicalTrials.gov
NCT03431168	A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV	Phase 2	308	2022-05-04	trimethoprim-sulfamethoxazole	A combination that names it	ClinicalTrials.gov
NCT00061945	Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia	Phase 1/2	302	2014-04-16	trimethoprim-sulfamethoxazole	A combination that names it	ClinicalTrials.gov

1 to 10 of 132

See all 132 trials

Comparisons in its trials106

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Asymptomatic Bacteriuria Following Short-course Versus Standard-course of Antibiotics.	11 of 328	29 of 336	664	NCT01595529	Trial comparisons
Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Clinical Symptoms That May be Related to a UTI Following Short-course Versus Standard-course of Antibiotics.	30 of 328	41 of 336	664	NCT01595529	Trial comparisons
Standard Course Treatment vs Short Course Treatment: Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics.	2 of 328	14 of 336	664	NCT01595529	Trial comparisons
Standard Course Treatment vs Short Course Treatment: deaths from any cause	0 of 328	0 of 336	664	NCT01595529	Trial comparisons
Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Positive Urine Cultures Following Short-course Versus Standard-course of Antibiotics.	6 of 328	41 of 336	664	NCT01595529	Trial comparisons
Standard Course Treatment vs Short Course Treatment: serious adverse events	2 of 328	4 of 336	664	NCT01595529	Trial comparisons
Standard Course Treatment vs Short Course Treatment: Comparison of Number of Subjects That Have a Recurrent Infection (Includes a Relapse UTI or a Reinfection) Following Short-course Versus Standard-course of Antibiotics.	12 of 326	13 of 322	648	NCT01595529	Trial comparisons
Standard Course Treatment vs Short Course Treatment: Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics. Per-protocol Population.	2 of 308	9 of 314	622	NCT01595529	Trial comparisons
Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Positive Urine Cultures Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population.	6 of 308	35 of 314	622	NCT01595529	Trial comparisons
Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Clinical Symptoms That May be Related to a UTI Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population	29 of 308	33 of 314	622	NCT01595529	Trial comparisons

1 to 10 of 106

See all 106 comparisons in its trials

Papers from its trials107

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29127863	RESULT	1	PubMed
29029337	RESULT	1	PubMed
28480292	RESULT	1	PubMed
28329368	RESULT	1	PubMed
27869362	RESULT	1	PubMed
27717402	RESULT	1	PubMed
27614925	RESULT	1	PubMed
26403465	RESULT	1	PubMed
25870429	RESULT	1	PubMed
25785967	RESULT	1	PubMed

1 to 10 of 107

See all 107 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL22

GET https://conductscience.org/api/drugs/v1/CHEMBL22/diseases?page=2

API reference For AI assistants